Table 3.
RNF43 hot‐spot mutations in MSI and MSS polyps from Lynch patients
| RNF43 | MS staining | HP (n = 37) | SSL (n = 11) | TA (n = 58) | TVA (n = 3) | Total (n = 109) |
|---|---|---|---|---|---|---|
| No hot‐spot mutation | MSI | – | – | 7 | 2 | 9 (8.2%) |
| MSS | 28 | 7 | 36 | 1 | 72 (66.0%) | |
| Unclear | 5 | 1 | 3 | – | 9 (8.2%) | |
| p.Arg117fs | MSI | – | – | 2 | – | 2 (1.8%) |
| MSS | – | 1 | – | – | 1 (0.9%) | |
| p.Gly659fs | MSI | 1 | 1 | 4 | – | 6 (5.5%) |
| MSS | 3 | 1 | 3 | – | 7 (6.4%) | |
| Both hot‐spot mutations | MSI | – | – | 3 | – | 3 (2.7%) |
| MSS | – | – | – | – | 0 (0%) |
MSI, Microsatellite‐instable; MSS, Microsatellite‐stable; MS, Microsatellite; MMR, Mismatch repair; HP, Hyperplastic polyp; SSL, Sessile serrated lesion; TA, Tubular adenema; TVA, Tubulovillous adenoma.
*
Immunohistochemistry for MMR genes normal staining pattern.